ReShape Lifesciences Inc. - FORM S-1 - EX-23.1 - CONSENT OF KPMG LLP - September 8, 2016

Attached files

file filename
EX-21.1 - SUBSIDIARY OF REGISTRANT - ReShape Lifesciences Inc.d223031dex211.htm
EX-16.1 - CONSENT OF ERNST AND YOUNG LLP - ReShape Lifesciences Inc.d223031dex161.htm
EX-10.10 - LOAN AND SECURITY AGREEMENT - ReShape Lifesciences Inc.d223031dex1010.htm
EX-10.9 - DISTRIBUTION AGREEMENT (BADER) - ReShape Lifesciences Inc.d223031dex109.htm
EX-10.8 - OFFICE LEASES - ReShape Lifesciences Inc.d223031dex108.htm
EX-10.2 - 2008 STOCK PLAN - ReShape Lifesciences Inc.d223031dex102.htm
EX-4.6 - SERIES E WARRANT - ReShape Lifesciences Inc.d223031dex46.htm
EX-4.5 - SERIES D WARRANT - ReShape Lifesciences Inc.d223031dex45.htm
EX-4.4 - SERIES C-1 WARRANT - ReShape Lifesciences Inc.d223031dex44.htm
EX-4.3 - FORM OF SERIES C WARRANT - ReShape Lifesciences Inc.d223031dex43.htm
EX-4.2 - INVESTORS' RIGHTS AGREEMENT - ReShape Lifesciences Inc.d223031dex42.htm
EX-4.1 - FORM OF COMMON STOCK CERTIFICATE - ReShape Lifesciences Inc.d223031dex41.htm
EX-3.3 - BYLAWS - ReShape Lifesciences Inc.d223031dex33.htm
EX-3.1 - SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - ReShape Lifesciences Inc.d223031dex31.htm
S-1 - S-1 - ReShape Lifesciences Inc.d223031ds1.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Obalon Therapeutics, Inc.:

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

 

  /s/ KPMG LLP

San Diego, California

September 8, 2016

ReShape Lifesciences Inc. Reports